Stock Analysis

Biovica International Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

OM:BIOVIC B
Source: Shutterstock

Biovica International (STO:BIOVIC B) Full Year 2024 Results

Key Financial Results

  • Net loss: kr124.8m (loss widened by 13% from FY 2023).
  • kr2.14 loss per share.
revenue-and-expenses-breakdown
OM:BIOVIC B Revenue and Expenses Breakdown July 4th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biovica International EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 27%. Earnings per share (EPS) exceeded analyst estimates by 71%.

The primary driver behind last 12 months revenue was the USA segment contributing a total revenue of kr5.58m (77% of total revenue). The largest operating expense was General & Administrative costs, amounting to kr123.5m (92% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of kr2.81m. Explore how BIOVIC B's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's shares are down 14% from a week ago.

Risk Analysis

Be aware that Biovica International is showing 5 warning signs in our investment analysis and 2 of those are significant...

Valuation is complex, but we're here to simplify it.

Discover if Biovica International might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.